Clinical trials market seen reaching $176.3 billion by 2030

The global clinical trials market is projected to grow from $135.51 billion in 2026 to $176.32 billion by 2030, driven by AI-enabled trial design, precision medicine, decentralized studies and faster drug development. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Clinical trials sit at the center of drug development, shaping whether new medicines can prove safety, effectiveness and dosing before regulatory approval. - Faster growth in clinical research can speed up access to new therapies for chronic and complex diseases. - The market’s expansion also points to rising demand for contract research, data tools and trial execution services.

What happened: - The Business Research Company released its Clinical Trials Market Report 2026, covering market size, trends and a global forecast through 2035. - The report estimates the clinical trials market will rise from $127.16 billion in 2025 to $135.51 billion in 2026. - The report projects the market will reach $176.32 billion by 2030, reflecting a 6.8% CAGR over the forecast period. - North America held the largest share of the global market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Historical growth has been supported by higher pharmaceutical R&D spending, broader global drug development pipelines, rising chronic disease prevalence, regulatory frameworks for clinical trials and greater outsourcing to CROs. - Future growth is expected to come from AI-enabled trial designs, precision medicine trials, decentralized and virtual clinical trials, stronger regulatory focus on real-world evidence and demand for faster drug approval. - The report defines clinical trials as controlled studies that test the safety, effectiveness, dosage and side effects of new drugs or medical treatments in human subjects. - These studies move through multiple phases and generate data used for regulatory approval and therapy development. - The report says the 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.

Between the lines: - The forecast suggests clinical trials are becoming more digital, more decentralized and more closely tied to AI and precision medicine. - Stronger demand for faster approvals and real-world evidence points to a market that is shifting from traditional site-based trials toward more flexible research models. - Europe’s reported pharmaceutical production growth in 2023 underscores the broader drug-development pipeline feeding demand for trials.

What's next: - The market is expected to keep expanding as drug developers, CROs and regulators adapt to new trial formats and data requirements. - Asia-Pacific’s growth outlook suggests more trial activity and investment will likely shift toward the region. - The Business Research Company said the report is available to support market sizing, forecasting and competitive analysis for industry stakeholders.

The bottom line: - Clinical trials remain a growing, tech-enabled core of the drug-development economy, with the strongest momentum coming from AI, decentralized studies and global expansion.